Evidence map›Paper›PMID 34980213›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

Induction of m

Zhiming Wang, Jin He, Duc-Hiep Bach, Yung-Hsing Huang, Zongwei Li, Huan Liu, Pei Lin, Jing Yang

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 122 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Emerging roles of RNA mInternational journal of oncology · 2026
    Review
  7. Article
  8. Article
  9. Research on exosomes in cancer multidrug resistance and clinical translation.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Zhiming WangHouston Methodist Cancer Center, Research Institute Houston Methodist Hospital, Houston, TX, 77030, USA.
Jin HeHouston Methodist Cancer Center, Research Institute Houston Methodist Hospital, Houston, TX, 77030, USA.
Duc-Hiep BachHouston Methodist Cancer Center, Research Institute Houston Methodist Hospital, Houston, TX, 77030, USA.
Yung-Hsing HuangHouston Methodist Cancer Center, Research Institute Houston Methodist Hospital, Houston, TX, 77030, USA.
Zongwei LiHouston Methodist Cancer Center, Research Institute Houston Methodist Hospital, Houston, TX, 77030, USA.
Huan LiuCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Pei LinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jing YangHouston Methodist Cancer Center, Research Institute Houston Methodist Hospital, Houston, TX, 77030, USA. jyang2@houstonmethodist.org.
Houston Methodist · USMethodist Hospital · USThe University of Texas MD Anderson Cancer Center · USXiamen University · CN

Funding

Role of integrin VLA-6 in suppression of bone formation in myelomaR01CA193362 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2016 to 2020
$1.8M
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myelomaR01CA190863 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA190863NCI NIH HHS R01 CA193362the national institutes of health CA190863the national institutes of health CA193362
6 · The paper itself

Abstract

backgroundTherapeutic resistance occurs in most patients with multiple myeloma (MM). One of the key mechanisms for MM drug resistance comes from the interaction between MM cells and adipocytes that inhibits drug-induced apoptosis in MM cells; MM cells reprogram adipocytes to morph into different characterizations, including exosomes, which are important for tumor-stroma cellular communication. However, the mechanism by which exosomes mediate the cellular machinery of the vicious cycle between MM cells and adipocytes remains unclear.

methodsAdipocytes were either isolated from bone marrow aspirates of healthy donors or MM patients or derived from mesenchymal stem cells. Co-culturing normal adipocytes with MM cells was used to generate MM-associated adipocytes. Exosomes were collected from the culture medium of adipocytes. Annexin V-binding and TUNEL assays were performed to assess MM cell apoptosis. Methyltransferase activity assay and dot blotting were used to access the m

resultsExosomes collected from MM patient adipocytes protect MM cells from chemotherapy-induced apoptosis. Two LncRNAs in particular, LOC606724 and SNHG1, are significantly upregulated in MM cells after exposure to adipocyte exosomes. The raised LncRNA levels in MM cells are positively correlated to worse outcomes in patients, indicating their clinical relevancy in MM. The functional roles of adipocyte exosomal LOC606724 or SNHG1 in inhibition of MM cell apoptosis are determined by knockdown in adipocytes or overexpression in MM cells. We discovered the interactions between LncRNAs and RNA binding proteins and identified methyltransferase like 7A (METTL7A) as an RNA methyltransferase. MM cells promote LncRNA package into adipocyte exosomes through METTL7A-mediated LncRNA m

conclusionThis study elucidates an unexplored mechanism of how adipocyte-rich microenvironment exacerbates MM therapeutic resistance and indicates a potential strategy to improve therapeutic efficacy by blocking this vicious exosome-mediated cycle.

Indexed as

AnimalsDisease Models, AnimalDrug Resistance, NeoplasmExosomesHumansMembrane GlycoproteinsMethylationMiceMice, KnockoutMultiple MyelomaNerve Tissue ProteinsRNA, Long NoncodingSignal TransductionTumor MicroenvironmentUp-RegulationGpm6a protein, mouseMembrane GlycoproteinsNerve Tissue ProteinsRNA, Long NoncodingAdipocytesExosomesLncRNA m6A MethylationMyelomaTherapeutics

Identifiers

PMID34980213
PMCPMC8722039
OpenAlexW4205087676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.